Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) EBT Margin (2018 - 2025)

10x Genomics' EBT Margin history spans 8 years, with the latest figure at 9.15% for Q4 2025.

  • For Q4 2025, EBT Margin rose 2017.0% year-over-year to 9.15%; the TTM value through Dec 2025 reached 6.21%, up 2289.0%, while the annual FY2025 figure was 6.21%, 2289.0% up from the prior year.
  • EBT Margin for Q4 2025 was 9.15% at 10x Genomics, up from 18.93% in the prior quarter.
  • Across five years, EBT Margin topped out at 21.4% in Q2 2025 and bottomed at 59.71% in Q3 2023.
  • The 5-year median for EBT Margin is 23.46% (2024), against an average of 24.28%.
  • The largest annual shift saw EBT Margin surged 35299bps in 2021 before it crashed -4710bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 11.14% in 2021, then rose by 6bps to 10.5% in 2022, then crashed by -141bps to 25.33% in 2023, then fell by -16bps to 29.32% in 2024, then surged by 69bps to 9.15% in 2025.
  • Per Business Quant, the three most recent readings for TXG's EBT Margin are 9.15% (Q4 2025), 18.93% (Q3 2025), and 21.4% (Q2 2025).